BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 12975670)

  • 1. [Role of gemcitabine/cisplatin in the treatment of advanced and metastatic bladder cancer].
    Bodrogi I
    Magy Onkol; 2003; 47(2):198-203. PubMed ID: 12975670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and future perspectives in advanced bladder cancer: is there a new standard?
    von der Maase H
    Semin Oncol; 2002 Feb; 29(1 Suppl 3):3-14. PubMed ID: 11894002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen.
    Adamo V; Magno C; Spitaleri G; Garipoli C; Maisano C; Alafaci E; Adamo B; Rossello R; Scandurra G; Scimone A
    Oncology; 2005; 69(5):391-8. PubMed ID: 16319510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
    Shelley M; Cleves A; Wilt TJ; Mason M
    Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasiblity study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function.
    Carles J; Suárez C; Mesía C; Nogué M; Font A; Doménech M; Suárez M; Tusquets I; Gallén M; Albanell J; Fabregat X
    Clin Transl Oncol; 2006 Oct; 8(10):755-7. PubMed ID: 17074675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SPIRE - combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial.
    Crabb S; Danson SJ; Catto JWF; McDowell C; Lowder JN; Caddy J; Dunkley D; Rajaram J; Ellis D; Hill S; Hathorn D; Whitehead A; Kalevras M; Huddart R; Griffiths G
    Trials; 2018 Apr; 19(1):216. PubMed ID: 29615077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Open-label randomized multi-center phase 2 study: gemcitabine cisplatin plus avelumab or gemcitabine cisplatin as first-line treatment of patients with locally advanced or metastatic urothelial bladder carcinoma: GCisAve.
    Gross-Goupil M; Domblides C; Lefort F; Ravaud A
    Bull Cancer; 2020 Jun; 107(5S):eS1-eS7. PubMed ID: 32620210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine in bladder cancer.
    Sternberg CN
    Semin Oncol; 2000 Feb; 27(1 Suppl 2):31-9. PubMed ID: 10697034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule?
    Als AB; Sengelov L; Von Der Maase H
    Acta Oncol; 2008; 47(1):110-9. PubMed ID: 17851853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The efficacy and toxicity of gemcitabine and cisplatin chemotherapy in advanced/metastatic bladder urothelial carcinoma].
    Gunlusoy B; Arslan M; Vardar E; Degirmenci T; Kara C; Ceylan Y; Kozacıoğlu Z
    Actas Urol Esp; 2012 Oct; 36(9):515-20. PubMed ID: 22819345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.
    Sternberg CN; Calabrò F; Pizzocaro G; Marini L; Schnetzer S; Sella A
    Cancer; 2001 Dec; 92(12):2993-8. PubMed ID: 11753976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Gemcitabine in advanced bladder cancer].
    Lehmann J; Retz M; Lippert C; Albers P; Stöckle M
    Urologe A; 2003 Jan; 42(1):63-77. PubMed ID: 12574885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium.
    Bellmunt J; Albiol S; de Olano AR; Pujadas J; Maroto P;
    Ann Oncol; 2006 May; 17 Suppl 5():v113-7. PubMed ID: 16807437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine doublets in advanced urothelial cancer.
    Stadler WM
    Semin Oncol; 2002 Feb; 29(1 Suppl 3):15-9. PubMed ID: 11894003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: a phase II study.
    Halim A; Abotouk N
    Asia Pac J Clin Oncol; 2013 Mar; 9(1):60-5. PubMed ID: 22897883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy.
    Kanai K; Kikuchi E; Ohigashi T; Miyajima A; Nakagawa K; Nakashima J; Oya M
    Int J Clin Oncol; 2008 Dec; 13(6):510-4. PubMed ID: 19093178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine in the treatment of bladder cancer.
    Ryan CW; Vogelzang NJ
    Expert Opin Pharmacother; 2000 Mar; 1(3):547-53. PubMed ID: 11249537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel gemcitabine-containing triplets in the management of urothelial cancer.
    Hussain M; Vaishampayan U; Smith DC
    Semin Oncol; 2002 Feb; 29(1 Suppl 3):20-4. PubMed ID: 11894004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine and cisplatin in locally advanced and/or metastatic bladder cancer.
    von der Maase H
    Eur J Cancer; 2000 Jul; 36 Suppl 2():13-6. PubMed ID: 10908843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Metastases from urethelial carcinoma: role of chemotherapy].
    Lebret T; Méjean A
    Prog Urol; 2008 Nov; 18 Suppl 7():S261-76. PubMed ID: 19070803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.